Some kinase fusions, such as anaplastic lymphoma kinase (ALK), v-ros UR2 sarcoma virus oncogene homolog 1 (ROS1), and rearranged during transfection (RET), have been well characterized in NSCLC, and tyrosine kinase inhibitors (TKIs) have become a standard treatment option for advanced NSCLC patients harboring these fusions [3–6]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.